Aberdeen Asset Management PLC UK reduced its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 7.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 87,068 shares of the company’s stock after selling 7,032 shares during the quarter. Aberdeen Asset Management PLC UK’s holdings in Zoetis were worth $5,431,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also bought and sold shares of the company. Assetmark Inc. increased its holdings in Zoetis by 4.6% during the 1st quarter. Assetmark Inc. now owns 1,918 shares of the company’s stock valued at $102,000 after acquiring an additional 85 shares in the last quarter. Guardian Life Insurance Co. of America increased its holdings in Zoetis by 0.7% during the 1st quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock valued at $102,000 after acquiring an additional 13 shares in the last quarter. Point72 Asia Hong Kong Ltd purchased a new position in Zoetis during the 1st quarter valued at about $111,000. First Interstate Bank increased its holdings in Zoetis by 3.5% during the 1st quarter. First Interstate Bank now owns 2,250 shares of the company’s stock valued at $120,000 after acquiring an additional 76 shares in the last quarter. Finally, Israel Discount Bank of New York purchased a new position in Zoetis during the 1st quarter valued at about $129,000. Hedge funds and other institutional investors own 93.31% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Aberdeen Asset Management PLC UK Sells 7,032 Shares of Zoetis Inc. (ZTS)” was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.chaffeybreeze.com/2017/09/16/aberdeen-asset-management-plc-uk-sells-7032-shares-of-zoetis-inc-zts.html.
Several equities analysts have weighed in on ZTS shares. Cantor Fitzgerald set a $75.00 target price on shares of Zoetis and gave the company a “buy” rating in a report on Monday, August 14th. Stifel Nicolaus reaffirmed a “buy” rating and set a $65.00 price target on shares of Zoetis in a research note on Friday, September 1st. Argus reaffirmed a “buy” rating and set a $69.00 price target (up from $60.00) on shares of Zoetis in a research note on Tuesday, May 30th. CL King assumed coverage on shares of Zoetis in a research note on Friday, May 26th. They set a “buy” rating and a $71.00 price target on the stock. Finally, Deutsche Bank AG reaffirmed a “buy” rating and set a $65.00 price target (up from $62.00) on shares of Zoetis in a research note on Monday, July 17th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. Zoetis presently has a consensus rating of “Buy” and an average price target of $65.44.
Shares of Zoetis Inc. (ZTS) opened at 65.20 on Friday. The company has a 50 day moving average of $62.29 and a 200 day moving average of $59.39. Zoetis Inc. has a 52-week low of $46.86 and a 52-week high of $65.83. The firm has a market capitalization of $31.89 billion, a PE ratio of 36.86 and a beta of 1.02.
Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 8th. The company reported $0.53 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.53. The company had revenue of $1.27 billion for the quarter, compared to the consensus estimate of $1.27 billion. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. The firm’s quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.49 EPS. On average, analysts anticipate that Zoetis Inc. will post $2.34 earnings per share for the current fiscal year.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.